26 related articles for article (PubMed ID: 20082499)
1. Value-based drug pricing in the Biden era: Opportunities and prospects.
Neumann PJ; Ollendorf DA; Cohen JT
Health Serv Res; 2021 Dec; 56(6):1093-1099. PubMed ID: 34085289
[No Abstract] [Full Text] [Related]
2. Take Care of the Fast-in-Human Study.
van Hoogdalem EJ
Clin Transl Sci; 2017 May; 10(3):122-123. PubMed ID: 27981812
[No Abstract] [Full Text] [Related]
3. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
4. [Patients, patents and profits].
Roland PC
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741
[No Abstract] [Full Text] [Related]
5. World Trade Organization still threatens supply of affordable AIDS drugs.
Hagmann M
Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
[No Abstract] [Full Text] [Related]
6. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
Sherrid P
US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
[No Abstract] [Full Text] [Related]
7. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
8. [Free trade agreements make the drugs more expensive].
Jeppsson A
Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
[No Abstract] [Full Text] [Related]
9. Are we living in the end of the blockbuster drug era?
Debnath B; Al-Mawsawi LQ; Neamati N
Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
[TBL] [Abstract][Full Text] [Related]
10. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G; Larrimore Ouellette L
JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
[No Abstract] [Full Text] [Related]
11. Review of the literature on reference pricing.
López-Casasnovas G; Puig-Junoy J
Health Policy; 2000 Nov; 54(2):87-123. PubMed ID: 11094265
[TBL] [Abstract][Full Text] [Related]
12. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Sarpatwari A; Kesselheim AS
PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
